| Literature DB >> 34945855 |
Arian Hosseinzadeh1, Mehdi Najafi1,2, Wisit Cheungpasitporn3, Charat Thongprayoon3, Mahdi Fathi4.
Abstract
In United States (U.S.), government-funded organizations, such as NLDAC, reimburse travel and subsistence expenses incurred during living-organ donation process. However, in Iran, there is a non-governmental organization called Iranian Kidney Foundation (IKF) that funds the direct and indirect costs of donors through charitable donations and contributions from participants in the exchange program. In this article, for countries outside the U.S. that currently use an equality approach, we propose a potential new compensation-apportionment approach (equitable approach) for kidney-exchange chains and compare it with the currently available system (equality approach) in terms of the apportionment of compensation in a kidney-exchange chain to cover the expenses incurred by the initiating living donor of the chain in the act of donation. To this end, we propose a mechanism to apportion compensation among all participating pairs based on the equity approach by utilizing a prediction model to calculate the probability of graft survival in each transplant operation. These probabilities are then used to define the utility of any transplantation, considering the quality of each pair's donated and received kidney in the chain. Afterward, the corresponding cost is apportioned by a mechanism based on the normalized differences between the utility of donated and received kidneys for each incompatible pair of the chain. In summary, we demonstrate that by utilizing the equitable approach, there is more fairness and equity in the allocation of resources in organ-procurement systems, which results in more satisfaction among incompatible pairs. Additional future prospective studies are needed to assess this proposed equitable approach for kidney-exchange chains in countries outside the U.S., such as Iran, that currently use an equality approach.Entities:
Keywords: equity; financial neutrality; graft survival prediction; kidney chain donation; kidney exchange
Year: 2021 PMID: 34945855 PMCID: PMC8709455 DOI: 10.3390/jpm11121383
Source DB: PubMed Journal: J Pers Med ISSN: 2075-4426
Figure 1An illustrative statement of the problem under investigation. A kidney-exchange chain with one initiating living donor, four incompatible pairs and a waiting-list recipient. Each incompatible pair makes a payment to the organ-procurement organization, and the total compensation is paid to the initiating donor.
Figure 2Interview structure based on SG technique. SG, standard gamble.
Average results of the interviews based on SG technique. SG, standard gamble.
| Stage | 1 | 2 | 3 | ||||
|---|---|---|---|---|---|---|---|
| Lottery | 1 | 2 | 3 | 4 | 5 | 6 | 7 |
| 10-Year Survival Probability | 35.0% | 16.0% | 55.0% | 6.5% | 24.0% | 42.0% | 73.0% |
| Utility | 0.500 | 0.250 | 0.750 | 0.125 | 0.375 | 0.625 | 0.875 |
Figure 3Relationship between probability of graft survival and utility of transplant.
Characteristics of transplants in the chain in scenarios 1 & 2. HLA, human leukocyte antigen. MM, mismatch. BMI, body mass index. PRA, panel reactive antibody.
| Characteristics | Transplant 1 Scenario 1 | Transplant 1 Scenario 2 | Transplant 2 | Transplant 3 | Transplant 4 | Transplant 5 |
|---|---|---|---|---|---|---|
| Living-donor Type | Unrelated | Unrelated | Unrelated | Unrelated | Unrelated | Unrelated |
| Recipient Age | 18–29 | 18–29 | 18–29 | 30–39 | 18–29 | 50–59 |
| Donor Age | 50–59 | <30 | 30–39 | 40–49 | <30 | <30 |
| Donor-Recipient Type | F-M | M-M | M-M | M-F | F-F | M-M |
| HLA ABDR MM | 1–2 HLA, Any DR | 1–2 HLA, Any DR | 1–2 HLA, 0 DR | 0 HLA | 0 HLA | 1–2 HLA, 0 DR |
| Recipient BMI | Not Obese (<30) | Not Obese (<30) | Not Obese (<30) | Not Obese (<30) | Obese (>30) | Not Obese (<30) |
| Donor BMI | Obese (>30) | Not Obese (<30) | Not Obese (<30) | Not Obese (<30) | Not Obese (<30) | Not Obese (<30) |
| Donor-Recipient Weight Ratio | >1.15 | 0.90–1.15 | 0.90–1.15 | 0.90–1.15 | 0.90–1.15 | 0.75–0.90 |
| Donor-Recipient Height Ratio | 1.00–1.06 | 1.00–1.06 | 1.00–1.06 | 1.00–1.06 | 1.00–1.06 | 0.94–1.00 |
| Recipient Race | White | White | White | White | White | White |
| Donor Race | Not Black or Hispanic | Not Black or Hispanic | Not Black or Hispanic | Not Black or Hispanic | Not Black or Hispanic | Not Black or Hispanic |
| Donor History of Cigarette Use | No | No | No | No | Yes | No |
| ABO Compatibility | Not Incompatible | Not Incompatible | Not Incompatible | Not Incompatible | Not Incompatible | Not Incompatible |
| PRA | 0–9 | 0–9 | 10–79 | 0–9 | 0–9 | 0–9 |
| Recipient Diagnosis | Not Diabetes | Not Diabetes | Not Diabetes | Not Diabetes | Not Diabetes | Not Diabetes |
| Previous Transplant | No | No | No | No | No | No |
| Time on Dialysis | 1–2 Years | 1–2 Years | 0–1 Years | 3+ Years | 0–1 Years | 2–3 Years |
| Recipient Hepatitis C Serology | Negative or Missing | Negative or Missing | Negative or Missing | Negative or Missing | Negative or Missing | Negative or Missing |
| Recipient Insurance | Public Primary Payer | Public Primary Payer | Public Primary Payer | Public Primary Payer | Public Primary Payer | Public Primary Payer |
| Transplant Year | 2008–2012 | 2008–2012 | 2008–2012 | 2008–2012 | 2008–2012 | 2008–2012 |
Survival probability and utility of transplants in the chain in scenarios 1 and 2.
| Survival Pr. and Utility of Transplants | Transplant 1 | Transplant 2 | Transplant 3 | Transplant 4 | Transplant 5 | |
|---|---|---|---|---|---|---|
| Scenario 1 | 10-Year Survival Probability | 46.20% | 55.40% | 73.70% | 57.40% | 64.80% |
| Estimated Utility | 0.65 | 0.73 | 0.87 | 0.75 | 0.81 | |
| Scenario 2 | 10-Year Survival Probability | 52.50% | 55.40% | 73.70% | 57.40% | 64.80% |
| Estimated Utility | 0.71 | 0.73 | 0.87 | 0.75 | 0.81 | |
Results of cost-apportionment process in scenario 1.
| Total Compensation = $5000 | Incompatible Pair 1 | Incompatible Pair 2 | Incompatible Pair 3 | Incompatible Pair 4 |
|---|---|---|---|---|
| Net Utility | −0.09 | −0.14 | 0.12 | −0.06 |
| Normalized Net Utility | 0.05 | 0 | 0.26 | 0.08 |
| Portion of Total Compensation Assigned | 13.60% | 0.00% | 66.30% | 20.10% |
| Assigned Cost ($) | 680 | - | 3313 | 1007 |
Results of cost-apportionment process in scenario 2.
| Total Compensation = $5500 | Incompatible Pair 1 | Incompatible Pair 2 | Incompatible Pair 3 | Incompatible Pair 4 |
|---|---|---|---|---|
| Net Utility | −0.03 | −0.14 | 0.12 | −0.06 |
| Normalized Net Utility | 0.11 | 0 | 0.26 | 0.08 |
| Portion of Total Compensation Assigned | 24.90% | 0.00% | 57.60% | 17.50% |
| Assigned Cost ($) | 1368 | - | 3169 | 963 |
Figure 4Frequency distribution of chain lengths.
Figure 5Frequency distribution of 10-year graft-survival probability.
Figure 6Frequency distribution of utility values.
Frequency distribution of 10-year survival outcomes of transplants.
| Transplant’s Outcome | Survived | Not-Survived |
|---|---|---|
| Frequency | 3948 | 4972 |
| Percentage Frequency | 44.3% | 55.7% |
Results of cost-apportionment process.
| Receiving Transplant’s Outcome | Survived | Not Survived | ||
|---|---|---|---|---|
| Approach | FCA | ECA | FCA | ECA |
| % of Total Compensation Paid | 52% | 44% | 48% | 56% |
| Average Compensation Paid ($) | 740 | 629 | 545 | 633 |
| Participants without Payment | 233 | - | 767 | - |
| % of Incompatible Pairs | 44% | 56% | ||
Reference Data for Utility Function.
| Probability of Graft Survival (10 Years Post Transplant) Extracted from Participants | Average Probability of Graft Survival (10 Years Post Transplant) | Utility | |||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | 2 | 3 | 4 | 5 | 6 | 7 | 8 | 9 | 10 | ||
| 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0.0% | 0.0% |
| 10% | 10% | 10% | 5% | 5% | 5% | 5% | 5% | 5% | 5% | 6.5% | 12.5% |
| 25% | 20% | 20% | 10% | 15% | 20% | 10% | 15% | 15% | 10% | 16.0% | 25.0% |
| 35% | 25% | 35% | 15% | 20% | 30% | 15% | 20% | 30% | 15% | 24.0% | 37.5% |
| 45% | 35% | 45% | 25% | 30% | 40% | 30% | 30% | 40% | 30% | 35.0% | 50.0% |
| 60% | 45% | 55% | 30% | 35% | 45% | 35% | 35% | 45% | 35% | 42.0% | 62.5% |
| 70% | 60% | 65% | 40% | 45% | 55% | 40% | 50% | 65% | 60% | 55.0% | 75.0% |
| 85% | 75% | 80% | 60% | 65% | 80% | 65% | 65% | 85% | 70% | 73.0% | 87.5% |
| 100% | 100% | 100% | 100% | 100% | 100% | 100% | 100% | 100% | 100% | 100.0% | 100.0% |